Pembrolizumab plus chemo without radiation for high PD-L1 lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether pembrolizumab combined with standard chemo can treat locally advanced, unresectable stage III lung cancer without giving radiation first. It is intended for people whose tumor has high PD-L1 (a marker linked to how well immunotherapy may work).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lung cancer that has been confirmed under a microscope (NSCLC)
- Your tumor PD-L1 test result is 50% or higher
- Your lung cancer is locally advanced stage III and cannot be removed with surgery
- You have not had any anti-cancer treatment for the main cancer yet
- Your scan shows at least one measurable cancer spot
- You are well enough to be active (ECOG 0–1) and your blood, kidney, liver, and thyroid tests meet trial limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.